Advanced NanoTherapies develops drug-coated balloons for vascular disease, using biodegradable nanoparticle delivery to release two drugs at the treatment site without leaving an implant behind. Its lead SirPlux Duo system is designed for coronary and peripheral artery applications, while the underlying platform is being explored for broader cardiovascular and endovascular uses. The company has completed its nanoparticle formulation and manufacturing infrastructure and is preparing for first-in-human trials; its products are not yet available for sale.
Cagent VascularCagent Vascular develops endovascular medical devices for peripheral artery disease, centered on its Serranator balloon catheters and Serration Remodeling Therapy. Co-founded by vascular surgeon Peter Schneider and inventor Robert Giasolli, the Wayne, Pennsylvania company uses focused point force rather than conventional circumferential stretching to open arteries at low pressure. Its platform includes a purpose-built catheter for difficult pedal and critical limb-threatening ischemia cases, alongside technologies still in development.WAYNE, PA
Nanobrid Innovations Private LimitedNanobrid Innovations Private Limited is an Indian nanotechnology company developing formulation solutions for drug delivery. Its proprietary Nanobrid® platform is intended to help deliver difficult-to-formulate active ingredients more effectively and conveniently for patients.RAJASTHAN, IN
VasocureVasocure is a novel therapeutics company developing peptide medicines for vascular disease, centered on Pedifin, its patented F11R blocker for neointimal disease and atherosclerosis. Founded by nephrologists and scientists involved in discovering the human F11 receptor, the company draws on more than two decades of research into vascular access failure in dialysis patients. Its 62-candidate pipeline spans nephrology, cardiology, and oncology, with Pedifin in preclinical and first-in-human studies.NEW YORK, NY
WaveClear VascularWaveClear Vascular is developing a proprietary ultrasonic catheter platform for removing vascular blood clots and calcified occlusions. Its approach combines more than one million controlled micro-cavitations per minute with acoustic micro-streaming and catheter motion, aiming to clear vessels while preserving vessel integrity and allowing targeted drug infusion. Founded by chief biophysicist Jeffrey Vaitekunas, whose career includes more than 25 patents and work on Johnson & Johnson’s UltraCision device, the company is led by a team with deep medical-device and vascular-care experience.